Patents Issued in December 14, 2004
-
Patent number: 6830884Abstract: The present invention relates generally to a method of amplifying closed circular nucleic acid probes and, more particularly, to a method of amplifying closed circular nucleic acid probes by rolling circle amplification. The method of the present invention is useful in a range of applications involving the detection of nucleic acid sequences such as, but not limited to, the identification of genetic disorders, genetic variants or the presence of microbiological or viral agents.Type: GrantFiled: December 14, 1999Date of Patent: December 14, 2004Assignee: Molecular Staging Inc.Inventors: Gregory John Hafner, Philip Morrison Giffard, Lindsay Colin Wolter, James Langham Dale, Mark Richard Stafford, Ilin Chen Hai-Ni Yang, Joanne Voisey
-
Patent number: 6830885Abstract: This invention relates to the screening of nucleic acids. More particularly, the present invention provides a dysfunctional viral genome capable of both expressing libraries of exogenous nucleic acids and selecting the sequences having a predefined characteristic or function within the cell, such as nucleic acids encoding signal peptides, secreted proteins, membrane bound proteins, proteases and drug-resistance proteins. The invention further provides a method and a kit for selecting nucleic acids having a desired feature, wherein production of a viral particle is dependent on insertion of an exogenous nucleic acid having the desired feature into a dysfunctional viral genome or into a viral genome exposed to a substance inhibiting viral packaging function(s).Type: GrantFiled: August 18, 2000Date of Patent: December 14, 2004Assignee: Phenogene Therapeutiques Inc.Inventors: Christian Lanctot, Pierre Moffat, Patrick Salois
-
Patent number: 6830886Abstract: The invention relates to a support. Oligonucleotides or polynucleotides are covalently bound with the 5′- or 3′-termination on least one main surface of said support via bifunctional spacers and bifunctional linkers.Type: GrantFiled: February 1, 2001Date of Patent: December 14, 2004Assignee: Memorec Medical Molecular Research Cologne Stoffel GmbHInventors: Andreas Bosio, Wilhelm Stoffel, Markus Stoffel
-
Patent number: 6830887Abstract: Quantitative and qualitative analysis of a nucleic acid analyte in a sample suspected to contain the nucleic acid analyte if achieved by first preparing a reaction mixture containing the sample and a known amount of an internal quantitation standard. At least a first aliquot of the reaction mixture is combined with a set of amplification reagents effective to amplify nucleic acids in the reaction mixture. The set of reagents includes at least one primer pair which is effective to amplify a first region of the nucleic acid analyte if present in the sample to produce a first amplified sample fragment and to amplify at least a portion of the internal quantitation standard to produce a control fragment. Amplification results in the formation of an amplification product mixture containing first amplified sample fragments and control fragments when the nucleic acid analyte is present in the sample, and only control fragments when the nucleic acid analyte is not present in the sample.Type: GrantFiled: February 25, 2002Date of Patent: December 14, 2004Assignee: Bayer HealthCare LLCInventor: Jean-Michel Lacroix
-
Patent number: 6830888Abstract: The invention provides methods to detect Legionella and further to detect L. pneumophila in biological samples using real-time PCR. Primers and probes for the detection of Legionella and L. pneumophila are provided by the invention. Articles of manufacture containing such primers and probes for detecting Legionella and L. pneumophila are further provided by the invention.Type: GrantFiled: May 7, 2002Date of Patent: December 14, 2004Assignee: Mayo Foundation for Medical Education and ResearchInventors: Franklin R. Cockerill, Randall T. Hayden, James R. Uhl
-
Patent number: 6830889Abstract: A practically usable DNA detection method by a DNA hybridization method with the use of fluorescent resonance energy transfer wherein the background luminescence based on the luminescence of a donor and the direct excitation of an acceptor) affecting the sensitized luminescence of the acceptor is minimized so that a target DNA strand can be conveniently and very easily detected in a homogeneous solution. In this DNA detection method, a DNA is detected by the DNA hybridization method by using, as detection reagents, streptoavidin labeled with a fluorescent rare earth metal complex, a nucleic acid probe modified with biotin and a nucleic acid probe labeled with an organic cyanine pigment and taking advantage of florescent resonance energy transfer.Type: GrantFiled: July 22, 2002Date of Patent: December 14, 2004Assignee: Japan Science and Technology AgencyInventors: Kazuko Matsumoto, Shinji Sueda
-
Patent number: 6830890Abstract: Libraries of unimolecular, double-stranded oligonucleotides on a solid support. These libraries are useful in pharmaceutical discovery for the screening of numerous biological samples for specific interactions between the double-stranded oligonucleotides, and peptides, proteins, drugs and RNA. In a related aspect, the present invention provides libraries of conformationally restricted probes on a solid support. The probes are restricted in their movement and flexibility using double-stranded oligonucleotides as scaffolding. The probes are also useful in various screening procedures associated with drug discovery and diagnosis. The present invention further provides methods for the preparation and screening of the above libraries.Type: GrantFiled: October 22, 2002Date of Patent: December 14, 2004Assignee: Affymetrix, Inc.Inventors: David J. Lockhart, Dirk Vetter, Martin Diggelmann
-
Patent number: 6830891Abstract: Methods for the diagnosis of ABPA in a human individual comprise determining if the individual carries antibodies reactive with one or more ABPA-related recombinant allergens, which one or more ABPA-related recombinant allergens discriminate between ABPA and allergic sensitization to A. fumigatus. Suitable allergens include rAsp F4, rAsp F6, rAsp F8, and ABPA-related fragments thereof which bind with IgE or IgG antibody.Type: GrantFiled: August 19, 1999Date of Patent: December 14, 2004Assignee: Pharmacia Diagnostics ABInventors: Reto Crameri, Stefanie Hemmann, Kurt Blaser
-
Patent number: 6830892Abstract: A method of screening for a target molecule from a group of potential target molecules is described. This method involves using a library of lentiviral vectors where the members encode the group of target molecules, then transducing a group of cells and screening the transduced cell for a desired phenotype. The cell(s) displaying the desired phenotype is selected and the target molecule is identified.Type: GrantFiled: September 14, 2001Date of Patent: December 14, 2004Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Sandra Ogueta
-
Patent number: 6830893Abstract: The present invention relates to the discovery that T20/DP178, T21/DP107, and fragments thereof interact with members of the formyl peptide receptor family and thereby modulate cell migration and activation. Novel biological tools, prophylactics, therapeutics and methods of use of the foregoing for modulating an inflammatory response are disclosed.Type: GrantFiled: November 2, 2001Date of Patent: December 14, 2004Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Ji Ming Wang, Joost J. Oppenheim, Shao-Bo Su, Wang Hua Gong, Ji-Liang Gao, Philip M. Murphy
-
Patent number: 6830894Abstract: Methods for using modulating agents to enhance or inhibit claudin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase blood/brain barrier permeability. The modulating agents comprise at least one claudin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the claudin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.Type: GrantFiled: November 3, 1999Date of Patent: December 14, 2004Assignee: Adherex Technologies, Inc.Inventors: Orest W. Blaschuk, James Matthew Symonds, Barbara J. Gour
-
Patent number: 6830895Abstract: The present invention relates to a kit for determining feline blood type, wherein the kit includes a mixture comprised of a first monoclonal antibody and a second monoclonal antibody, wherein both antibodies recognize feline blood group specific A antigens. The present invention also relates to a method for determining feline blood type, wherein the method utilizes two distinct monoclonal antibodies, which recognize feline blood group specific A antigens.Type: GrantFiled: July 26, 2001Date of Patent: December 14, 2004Assignee: Kansas State University Research FoundationInventors: Gordon A. Andrews, Joseph E. Smith
-
Patent number: 6830896Abstract: The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured.Type: GrantFiled: November 15, 2002Date of Patent: December 14, 2004Inventors: Noboru Kaneko, Ryuko Matsuda, Tadahiro Kajita
-
Patent number: 6830897Abstract: This invention provides a high throughput method for identifying drug candidates which produce reactive metabolites that contribute to toxicity of the drug product.Type: GrantFiled: April 18, 2001Date of Patent: December 14, 2004Assignee: Pfizer Inc.Inventors: Michael J. Avery, Weichao G. Chen, Hassan G. Fouda
-
Patent number: 6830898Abstract: The present invention features methods for the identification of compounds and compositions useful as antibiotics and antibacterial agents. In particular, the invention features methods for the identification of modulators of a previously unidentified target protein, termed CoaX. High-throughput assay systems are featured as well as assay kits for the identification of CoaX modulators. Also featured are coaX nucleic acid molecules and purified CoaX proteins, as well as recombinant vectors and microorganisms including the gene, coaX.Type: GrantFiled: March 20, 2001Date of Patent: December 14, 2004Assignee: OmniGene Bioproducts, Inc.Inventors: R. Rogers Yocum, Thomas A. Patterson
-
Patent number: 6830899Abstract: A transformed mutant, P. mendocina, is provided containing a DNA fragment that inactivates all pobA genes and encodes the enzyme hydroxybenzoate hydroxylase. Mutants deficient in hydroxybenzoate hydroxylase are useful for the production of para-hydroxybenzoate (PHBA).Type: GrantFiled: June 3, 1998Date of Patent: December 14, 2004Assignee: E. I. du Pont de Nemours and CompanyInventors: Kevin K. Chen, Rebecca Lynn Grelak
-
Patent number: 6830900Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the transporter peptides, and methods of identifying modulators of the transporter peptides.Type: GrantFiled: March 29, 2001Date of Patent: December 14, 2004Assignee: Applera CorporationInventors: Chunhua Yan, Ming-Hui Wei, Valentina Di Francesco, Ellen M. Beasley
-
Patent number: 6830901Abstract: An endogenous plasmid of Propionibacterium is described, isolated from Propionibacteria freudenreichii LMG 16545 (deposited as CBS 101022), and its sequence provided. This plasmid can be used to transform Propionibacteria to express homologous or heterologous proteins, in the production of recombinant proteins or products of enzymes, for example vitamin B12.Type: GrantFiled: June 25, 2001Date of Patent: December 14, 2004Assignee: DSM IP Assets B.V.Inventors: Pieter Hendrik Pouwels, Nicole Van Luijk, Johannes P. M. Jore, Rudolf G. M. Luiten
-
Patent number: 6830902Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: GrantFiled: June 30, 2000Date of Patent: December 14, 2004Assignee: Invitrogen CorporationInventors: Mekbib Astatke, Deb K. Chatterjee, Gary F. Gerard
-
Patent number: 6830903Abstract: The present invention relates, in general, to a method of producing L-amino acids comprising culturing altered bacterial cells having increased amounts of NADPH as compared to unaltered bacterial cells whereby L-amino acids yields from said altered bacterial cells are greater than yields from unaltered bacterial cells. The invention also relates to a gene encoding phosphoglucoisomerase.Type: GrantFiled: July 21, 2000Date of Patent: December 14, 2004Assignee: Archer-Daniels-Midland CompanyInventors: Michael R. O'Donohue, Paul D. Hanke
-
Patent number: 6830904Abstract: Methods for producing single diastereomers of isoleucine in high stereochemical purity are provided. D-isoleucine is produced by converting (R)-2-methylbutyraldehyde to a diastereomeric mixture of D-isoleucine hydantoin and L-allo-isoleucine hydantoin (5S-[(R)-1-methylpropyl]hydantoin) under conditions whereby no significant racemization of the chiral center in (R)-2-methylbutyraldehyde occurs, followed by contacting said diastereomeric hydantoin mixture with a D-hydantoinase to stereoselectively hydrolyze any D-isoleucine hydantoin in the mixture to the corresponding N-carbamoyl-D-isoleucine, preferably under conditions permitting the simultaneous epimerization of the chiral center at C-5 of the hydantoin. The simultaneous epimerization permits the reaction to be carried out to substantial completion so that the diastereomeric hydantoin mixture is converted to N-carbamoyl-D-isoleucine in high yield. The N-carbamoyl-D-isoleucine is then decarbamoylated to produce D-isoleucine.Type: GrantFiled: August 30, 2002Date of Patent: December 14, 2004Assignee: BioCatalytics, Inc.Inventors: J. David Rozzell, Jr., Basil P. Paulson
-
Patent number: 6830905Abstract: Glutaminase is purified from an Aspergillus oryzae, its partial amino acid sequence is determined, a partial sequence of glutaminase gene is obtained by PCR based on the obtained information, and DNA fragments containing glutaminase gene from Aspergillus oryzae genomic library and cDNA library, and Aspergillus nidulans genomic library hybridization using the partial sequence as a probe.Type: GrantFiled: October 2, 2002Date of Patent: December 14, 2004Assignee: Ajinomoto Co., Inc.Inventors: Kyoko Koibuchi, Hiroaki Nagasaki, Ari Yuasa, Jiro Kataoka, Katsuhiko Kitamoto
-
Patent number: 6830906Abstract: Methods and compositions are provided for the production of human manganese superoxide dismutase and a protocol for enhancing efficiency of expression. The gene encoding for human manganese superoxide dismutase was isolated and inserted into a vector in conjunction with a synthetic linker which provides for enhanced efficiency in translation. E. coli strain HB101 containing the plasmid Nco5AHSODm was deposited at the A.T.C.C. on Oct. 3, 1986 and given Accession No. 67191.Type: GrantFiled: June 11, 2001Date of Patent: December 14, 2004Assignee: Chiron CorporationInventors: Robert Alexander Hallewell, Graeme Ian Bell, Guy Towns Mullenbach
-
Patent number: 6830907Abstract: An objective of the present invention is to provide polypeptides capable of retaining a strong enzyme activity of formate dehydrogenase in the presence of an organic solvent and to provide the uses thereof. Formate dehydrogenase mutant polypeptides, which are resistant to organic solvents, were constructed by substituting cysteines at position 146 and/or at position 256 in the amino acid sequence of Mycobacterium vaccae-derived formate dehydrogenase by site-directed mutagenesis. The polypeptides have strong activities of formate dehydrogenase in the presence of an organic solvent. The mutants are useful for the production of alcohols using ketones as raw material, etc.Type: GrantFiled: November 28, 2001Date of Patent: December 14, 2004Assignee: Daicel Chemical Industries, Ltd.Inventors: Kazuya Mitsuhashi, Hiroaki Yamamoto, Norihiro Kimoto
-
Patent number: 6830908Abstract: The present invention provides a protein having &bgr;1,4-galactosyltransferase activity, DNA encoding the protein, a recombinant DNA comprising the DNA, a transformant carrying the recombinant DNA, a process for producing &bgr;1,4-galactosyltransferase by using the transformant, and a process for producing a galactose-containing carbohydrate by using the transformant.Type: GrantFiled: August 15, 2002Date of Patent: December 14, 2004Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Satoshi Koizumi, Tetsuo Endo, Kazuhiko Tabata, Akio Ozaki
-
Patent number: 6830909Abstract: A novel S6 kinase, p70&bgr;S6k, is described, along with methods of making and using p70&bgr;S6k and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70&bgr;S6k and/or its ligands.Type: GrantFiled: May 29, 2001Date of Patent: December 14, 2004Assignee: Ludwig Institute for Cancer ResearchInventors: Ivan Gout, Kenta Hara, Mike Waterfield, Kazu Yonezawa
-
Patent number: 6830910Abstract: The invention encompasses Drosophila Recombination Associated Protein (DRAP) isolated D. melanogaster and a nucleic acid sequence encoding DRAP. The Drosophila Recombination Associated Protein, its homologues from other organisms or active peptides derived therefrom, as well as DNA encoding such protein are useful for homology-dependent pairing of three DNA strands. The combination of strand-transfer and topoisomerase activities associated with DRAP permits directed pairing and cleavage at defined site(s) within DNA. This in turn makes possible the isolation and/or removal of a defined segment of DNA. DRAP is also useful in cloning, genomic cloning and gene mapping, in promoting gene disruptions or “knockout” mutations, in carrying out targeted mutagenesis of specific genes and in generating transgenic animals.Type: GrantFiled: July 19, 2002Date of Patent: December 14, 2004Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Andrew Eisen
-
Patent number: 6830911Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.Type: GrantFiled: February 8, 2002Date of Patent: December 14, 2004Assignee: Applera CorporationInventor: Zhaoxi Ke
-
Patent number: 6830912Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.Type: GrantFiled: October 31, 2003Date of Patent: December 14, 2004Assignee: Applera CorporationInventors: Douglas Rusch, Karen A. Ketchum, Valentina Di Francesco, Ellen M. Beasley
-
Patent number: 6830913Abstract: The invention provides isolated nucleic acid molecules, designated ABCB9 transporter nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ABCB9 transporter nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ABCB9 transporter gene has been introduced or disrupted. The invention still further provides isolated ABCB9 transporter proteins, fusion proteins, antigenic peptides, anti-ABCB9 transporter antibodies, and screening assays for ABCB9 transporter modulators. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 28, 2000Date of Patent: December 14, 2004Assignee: Active Pass Pharmaceuticals, Inc.Inventors: Victor Ling, Michelle L. Pollard, Bruce P. Connop, Fang Zhang
-
Patent number: 6830914Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 27, 2001Date of Patent: December 14, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, David Yowe
-
Patent number: 6830915Abstract: The present invention relates to genes which code for glycosyl hydrolases having an HCA score with the iota-carrageenase of Alteromonas fortis which is greater than or equal to 65% over the domain extending between amino acids 164 and 311 of the protein sequence SEQ ID No. 2 of said iota-carrageenase, and to genes which code for glycosyl hydrolases having an HCA score with the kappa-carrageenase of Alteromonas carrageenovora which is greater than or equal to 75% over the domain extending between amino acids 117 and 262 of the protein sequence SEQ ID No. 6 of said kappa-carrageenase.Type: GrantFiled: November 19, 2001Date of Patent: December 14, 2004Assignee: Laboratoires Goemar, S.A.Inventors: Tristan Barbeyron, Philippe Potin, Christophe Richard, Bernard Henrissat, Jean-Claude Yvin, Bernard Kloareg
-
Patent number: 6830916Abstract: The invention provides molecules that encode sphingosine kinase, the enzyme that catalyzes the phosphorylation of sphingosine to form sphingosine-1-phosphate (SPP). Vectors and host cells which express sphingosine kinase are also provided, as are methods for evaluating the stimulatory or inhibitory effects of agents on sphingosine kinase production and activity.Type: GrantFiled: March 2, 2001Date of Patent: December 14, 2004Inventor: Sarah Spiegel
-
Patent number: 6830917Abstract: The present invention is directed to methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease in a single affinity chromatography step and uses of the purified SGT.Type: GrantFiled: December 10, 2001Date of Patent: December 14, 2004Assignee: Baxter Healthcare S.A.Inventors: Artur Mitterer, Christa Tauer, Manfred Reiter, Wolfgang Mundt
-
Patent number: 6830919Abstract: A neutral/alkaline ceramidase derived from a mammal; an antibody specifically binding thereto; a probe and primer which are capable of specifically hybridizing thereto; a method for producing the ceramidase by a genetic engineering means; a method for detecting the ceramidase or the gene; and a method of controlling an amount of a ceramide in a cell and/or in a tissue. The present invention is useful as a reagent for lipid engineering for analyzing a structure, functions, and the like of a ceramide, and in its applications to diseases associated with the ceramide metabolism.Type: GrantFiled: September 26, 2001Date of Patent: December 14, 2004Assignee: Takara Bio Inc.Inventor: Makoto Ito
-
Patent number: 6830920Abstract: The invention provides a novel Adenovirus backbone plasmid, which when co-transfected with a shuttle vector, allows for production of recombinant viruses quickly and easily. The present invention also provides host cells and a cloning system for generating recombinant adenoviruses.Type: GrantFiled: March 8, 2000Date of Patent: December 14, 2004Assignee: University of Iowa Research FoundationInventors: Beverly L. Davidson, Richard Anderson, Ronald Haskell, Haibin Xia
-
Patent number: 6830921Abstract: The invention relates to an isolated polynucleotide comprising a polynucleotide sequence chosen from the group consisting of a) polynucleotide which is identical to the extent of at least 70 % to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2, b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70 % to the amino acid sequence of SEQ ID No. 2, c) polynucleotide which is complementary to the polynucleotides of a) or b), and d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c), a process for the fermentative preparation of L-amino acids with enhancement of the acp gene and the use of the polynucleotide as a primer or hybridization probe.Type: GrantFiled: May 10, 2001Date of Patent: December 14, 2004Assignee: Degussa AGInventors: Bettina Möckel, Anke Weissenborn, Walter Pfefferle, Hermann Sahm, Lothar Eggeling, Madhavan Nampoothiri
-
Patent number: 6830922Abstract: A system and method are provided for inoculating a biological reactor having a chamber. The chamber is configured to contain influent and biomass to degrade contaminants in the influent. A vessel is configured to receive influent and biomass from the chamber and to substantially isolate the received influent and biomass from that contained in the chamber. The vessel is also configured to deliver the isolated influent and biomass to the chamber, thereby facilitating inoculation of the biological reactor.Type: GrantFiled: December 21, 2001Date of Patent: December 14, 2004Assignee: Envirogen, Inc.Inventors: Raymond Jasienski, Younghua Yang
-
Patent number: 6830923Abstract: The invention relates to a genetic unit, optionally present as a multiple-copy, for inhibiting RNA. The unit contains the transcription units necessary for transcription by polymerase III and a DNA coding for inhibiting RNA, which is arranged within the unit in such a way that the transcribed RNA is part of the polymerase III transcript. Using these units it is possible to achieve increased stability of the inhibiting RNA, which may occur in the form of ribozymes or antisense-RNAs, whilst maintaining an undiminished activity. The invention further relates to a process for introducing the genetic units into the cell, the use of these units and pharmaceutical preparations containing them.Type: GrantFiled: September 21, 1992Date of Patent: December 14, 2004Assignee: Boehringer Inglheim International GmbHInventors: Hartmut Beug, Max L. Birnstiel, Matthew Cotten, Ernst Wagner, Harald Kandolf
-
Patent number: 6830924Abstract: The invention relates to newly identified cancer associated antigens, referred to as CT7, KOC-2 and KOC-3. The invention also relates to observations regarding known molecule KOC-1. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.Type: GrantFiled: March 16, 1999Date of Patent: December 14, 2004Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Cornell Research Foundation, Inc.Inventors: Yao-Tseng Chen, Ali Gure, Solam Tsang, Elisabeth Stockert, Elke Jager, Alexander Knuth, Lloyd J. Old
-
Patent number: 6830925Abstract: Methods for isolating CaMK-X1 genes are provided. The CaMK-X1nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.Type: GrantFiled: September 20, 2001Date of Patent: December 14, 2004Assignee: QLT Inc.Inventors: Thillainathan Yoganathan, Allen Delaney
-
Patent number: 6830926Abstract: The present invention provides a method for evaluating the ability of a compound to inhibit protoporphyrinogen oxidase activity, which comprises the steps of (1) culturing a transformant expressing a heterologous protoporphyrinogen oxidase (PPO) gene in a medium containing substantially no protoheme compounds in the presence and absence of a test compound to measure the growth rate of the transformant, wherein the transformant is a host cell deficient in PPO activity which is transformed with the heterologous PPO gene, and (2) determining the ability of the compound to inhibit the protoporphyrinogen oxidase activity by comparing growth rates.Type: GrantFiled: October 18, 2001Date of Patent: December 14, 2004Assignee: Sumotimo Chemical Company LimitedInventor: Yasutaka Shimokawatoko
-
Patent number: 6830927Abstract: A method of generating neural crest stem cells involves inducing neuroepithelial stem cells to differentiate in vitro into neural crest stem cells. Differentiation can be induced by replating the cells on laminin, withdrawing mitogens, or adding dorsalizing agents to the growth medium. Derivatives of the peripheral nervous system can be generated by inducing the neural crest stem cells to differentiate in vitro.Type: GrantFiled: May 6, 1998Date of Patent: December 14, 2004Assignee: University of Utah Research FoundationInventors: Mahendra S. Rao, Tahmina Mujtaba
-
Patent number: 6830928Abstract: The present invention relates to a method for the in vitro preparation of starting materials for micropropagation and/or storage of germplasm, comprising the steps of contacting plant material with a microorganism that induces fasciation and/or one or more fasciation-inducing factors derived from the microorganism or derived from the infected and/or fasciated tissue; developing leafy galls or shoot outgrowths on the plant material; and isolating the leafy galls or shoot outgrowths as the starting materials.Type: GrantFiled: November 24, 1999Date of Patent: December 14, 2004Assignees: Vlaam Interuniversitair Instituut Voor Biotechnologie, Universite Libre de BruxellesInventors: Koenraad Hilaire Maria Goethals, Mondher El Jaziri, Marc Charles Ernest Van Montagu
-
Patent number: 6830929Abstract: The invention relates to constructs capable of infecting mammalian cells comprising at least one semi-purified or pure SV40 capsid protein and a constituent selected from the group consisting of an exogenous DNA, a vector comprising an exogenous DNA, an exogenous RNA, a vector comprising an exogenous RNA, an exogenous protein or peptide product, and antisense RNA, ribozyme RNA or any RNA or DNA which inhibits or prevents the expression of undesired protein(s) in the mammalian cell and optionally further comprising operatively linked regulatory elements sufficient for the expression and/or replication of the exogenous protein in a mammalian cell. The invention further relates to a method for the in vitro construction of SV40 virus or pseudovirus constructs according to the invention.Type: GrantFiled: May 6, 1998Date of Patent: December 14, 2004Assignees: Yissum Research Development Company of the Hebrew University, Hadasit Medical Research Services and Development CompanyInventors: Ziv Sandalon, Amos Oppenheim, Ariella Oppenheim
-
Patent number: 6830930Abstract: The GAI gene of Arabidopsis thaliana has been cloned, along with mutant and homologue gene sequences. Expression of such genes a plants affects characteristics in the plants including growth. GAI expression inhibits growth of plants, which inhibition is antagonized by gibberellin (GA). Expression of gai mutants confers a dwarf phenotype which is GA-insensitive. Manipulation of expression of GAI and gai genes in plants results in tall or dwarfed plants. Dwarf plants are useful in particular for reduction in crop losses resulting from lodging.Type: GrantFiled: July 25, 2001Date of Patent: December 14, 2004Assignee: Pioneer Hi-Bred International, Inc.Inventors: Nicholas P. Harberd, Jinrong Peng, Pierre Carol, Donald E. Richards
-
Patent number: 6830931Abstract: An apparatus for monitoring proteins and cells. The apparatus includes a plate having wells in which cells are disposed. The apparatus includes means for analyzing the effect or proteins and other biological and chemical moieties on the cells. A method for monitoring of proteins and cells. A method for analyzing a cells. An apparatus for aligning light in a well of a plate for holding cells. A method for lighting a well. A method for determining a condition of a cell. An apparatus for indicating a condition of a cell. A method for establishing a focus profile of a plate having wells for holding cells. A method for manipulating cells. An apparatus for manipulating cells.Type: GrantFiled: October 26, 2001Date of Patent: December 14, 2004Assignee: Automated Cell, Inc.Inventors: Alfred Blalock Bahnson, Douglas J. Koebler, Charalambos N. Arthanassiou, Raymond K. Houck, Kris Sachsenmeier, Lei Qian
-
Patent number: 6830932Abstract: The invention relates to an in vitro method of recognizing acute coronary syndroms, especially an acute myocardial infarction, by determining and evaluating the content of choline, choline and/or trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline, and/or the reaction products thereof selected from the group comprising 1-O-alk-1′-enyl-2 substituted glycerol and 1-O-alk-1′-enyl-2 substituted glycerol phosphate in body fluids or component parts of the body, said method comprising the following steps: drawing a sample of a suitable body fluid or component part of the body; determining the content of choline, choline and/or trimethyl ammonium derivatives selected from the group comprising phosphoryl choline, plasmalogens, and lysoplasmenyl choline, and/or the reaction products thereof selected from the group comprising 1-O-alk-1′-enyl-2 substituted glycerol and 1-O-alk-1′-enyl-2 substituted glycerol phosphate by a sType: GrantFiled: February 9, 2001Date of Patent: December 14, 2004Inventors: Oliver Danne, Ulrich Frei, Adolf Zschunke, Clemens Mügge
-
Patent number: 6830933Abstract: Amlodipine aspartate and amlodipine maleamide are used as reference standards or markers in determining the purity of amlodipine maleate substances and products.Type: GrantFiled: August 27, 2001Date of Patent: December 14, 2004Assignee: Synthon BVInventors: Jacobus M Lemmens, Theodorus H. A. Peters, Peter F. A. Bakker, Frantisek Picha
-
Patent number: 6830934Abstract: A medical diagnostic device has a non-absorbent substrate that has a hydrophilic target area on which a reagent is deposited by non-impact printing of microdroplets. During deposition, the device is moved relative to the stream of microdroplets to form a substantially uniform reagent layer on the substrate. The device is particularly well adapted for measuring blood coagulation times. In a preferred embodiment, coagulation times are determined by monitoring the optical transmission of light through the target area as an applied blood sample interacts with the reagent.Type: GrantFiled: December 3, 1999Date of Patent: December 14, 2004Assignee: LifeScan, Inc.Inventors: Ian A. Harding, Robert Justice Shartle, Glenn Renowitzky, Lewis Leung